Literature DB >> 29882679

RAMP3 is a prognostic indicator of liver cancer and might reduce the adverse effect of TP53 mutation on survival.

Aiping Fang1,2, Shijie Zhou1,2,3, Xiaolan Su2, Chuang Liu2, Xiaoxin Chen3, Yang Wan1, Xiaohong Lei1, Linshen Xie1, Yiping Jia1, Wenzhi Wang1, Luo Yang1, Xuejiao Song1, Yuqin Yao1,2,3.   

Abstract

AIM: To assess the prognostic value of RAMP3 expression in terms of overall survival (OS) and recurrence-free survival (RFS) in hepatocellular carcinoma (HCC) patients. MATERIALS &
METHODS: Immunochemistry staining was performed to detect RAMP3 expression. Data in the Cancer Genome Atlas-Liver Hepatocellular Cancer were used for secondary analysis.
RESULTS: RAMP3 expression was significantly downregulated in HCC tissues than in normal liver tissues. Increased RAMP3 expression was an independent prognostic factor of favorable OS (hazard ratio [HR]: 0.772, 95% CI: 0.689-0.864; p < 0.001) and RFS (HR = 0.719, 95% CI: 0.633-0.817; p < 0.001). High RAMP3 expression was associated with significantly better RFS in both TP53 mutant and wildtype groups.
CONCLUSION: High RAMP3 RNA expression is an independent prognostic factor of favorable OS and RFS in patients with HCC.

Entities:  

Keywords:  RAMP3; hepatocellular carcinoma; overall survival; recurrence-free survival

Mesh:

Substances:

Year:  2018        PMID: 29882679     DOI: 10.2217/fon-2018-0296

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  8 in total

1.  Transcriptional and epigenetic landscape of Ca2+-signaling genes in hepatocellular carcinoma.

Authors:  Andrés Hernández-Oliveras; Eduardo Izquierdo-Torres; Guadalupe Hernández-Martínez; Ángel Zarain-Herzberg; Juan Santiago-García
Journal:  J Cell Commun Signal       Date:  2021-01-04       Impact factor: 5.782

2.  Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.

Authors:  Rui Li; Weiheng Zhao; Rui Liang; Chen Jin; Huihua Xiong
Journal:  Front Mol Biosci       Date:  2022-06-30

3.  EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma.

Authors:  Ji Yun Lee; Joo Hyun Kim; Heejin Bang; Junhun Cho; Young Hyeh Ko; Seok Jin Kim; Won Seog Kim
Journal:  Sci Rep       Date:  2021-05-14       Impact factor: 4.379

4.  Cell Differentiation Trajectory in Liver Cirrhosis Predicts Hepatocellular Carcinoma Prognosis and Reveals Potential Biomarkers for Progression of Liver Cirrhosis to Hepatocellular Carcinoma.

Authors:  Zhaobin He; Cheng Peng; Tianen Li; Jie Li
Journal:  Front Genet       Date:  2022-03-10       Impact factor: 4.599

5.  Identidication of novel biomarkers in non-small cell lung cancer using machine learning.

Authors:  Fangwei Wang; Qisheng Su; Chaoqian Li
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

6.  Transcript levels of spindle and kinetochore-associated complex 1/3 as prognostic biomarkers correlated with immune infiltrates in hepatocellular carcinoma.

Authors:  De-Chen Yu; Xiang-Yi Chen; Xin Li; Hai-Yu Zhou; De-Quan Yu; Xiao-Lei Yu; Yi-Cun Hu; Rui-Hao Zhang; Xiao-Bo Zhang; Kun Zhang; Jiang-Dong An
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

7.  Classification of early and late stage liver hepatocellular carcinoma patients from their genomics and epigenomics profiles.

Authors:  Harpreet Kaur; Sherry Bhalla; Gajendra P S Raghava
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

8.  PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer.

Authors:  Wei Xia; Hansong Bai; Ying Deng; Yi Yang
Journal:  J Cell Mol Med       Date:  2020-09-27       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.